Terns also expects to grant underwriters a 30-day option to buy up to an additional $60 million of shares. Later on Wednesday, Terns said it would price a separate public offering of 16.3 million ...

PVEK, a CD123-targeting antibody-drug conjugate, demonstrated strong response rates in two studies. Combined with VEN/AZA, it ...

MONTREAL, Dec. 10, 2025 /CNW/ - Novartis Canada is pleased to announce that Scemblix ® (asciminib) is one of the first therapies to be prioritized for public reimbursement under Ontario's new Funding ...

Researchers from The University of Texas MD Anderson Cancer Center presented promising new data from two ongoing studies of ...

A pioneering genetic treatment is saving lives where chemotherapy failed, offering new hope for children and adults with ...

A breakthrough therapy is driving aggressive leukaemia into remission. Here’s what the headlines don’t tell you about life after treatment.

Scientists at UCL and GOSH have used groundbreaking base-edited CAR‑T cell therapy — BE‑CAR7 — to treat aggressive T‑cell ...